BANOOK acquired by MOTION EQUITY PARTNERS

PharmaCord has been acquired by a company backed by Permira following a definitive agreement signed in June 2024. The transaction introduces new capital to PharmaCord while the existing management team, led by founder and CEO Nitin Sahney, retains operational control and a significant equity position. The investment is subject to customary regulatory approvals and is anticipated to close in the fourth quarter of 2024. Financial advisers to PharmaCord were Centerview Partners, with legal counsel provided by Willkie Farr & Gallagher; Permira’s advisers included Jefferies LLC and Leerink Partners, and its legal counsel was Skadden, Arps, Slate, Meagher & Flom LLP

21 Invest France acquired a majority stake in ProductLife Group from its founder who sought to institutionalize the company and secure resources for its next growth phase. The transaction was structured to allow the management team to reinvest significantly alongside 21 Invest. The strategic roadmap was focused on transforming PLG into an undisputed global leader through massive international consolidation.

Cerba HealthCare acquired the Canadian CRO Cirion BioPharma Research to integrate it into its global clinical trial business unit, Cerba Research. This move establishes a critical operational hub in North America, allowing the group to offer seamless cross-continental support for drug development programs. The transaction followed Cerba's previous major international acquisitions of Lifebrain (Italy) and Viroclinics-DDL (Netherlands), furthering the global expansion strategy initiated under EQT's majority ownership since 2021

Permira acquired Ergomed in a recommended cash offer, taking the company private from the London Stock Exchange (AIM). The transaction was driven by the thesis that Ergomed's next phase of growth—requiring significant investment in technology and international expansion (particularly in the US)—could be better executed away from the public markets. The deal structure allowed the founder, Miroslav Reljanović, to roll over a portion of his equity and remain involved, ensuring continuity. Strategically, Permira aims to supercharge Ergomed's "Site Management" model and its pharmacovigilance capabilities through both organic investment and accretive M&A

Gleamer raised €27 million in Series B funding to broaden its AI solution portfolio and accelerate global commercial development. The strategic plan involves expanding the software suite to include CT scans and mammography, aiming to cover 70% of radiologists' daily diagnostic needs. A significant portion of the capital is earmarked for strengthening commercial and technical teams in Europe and the United States, as well as deepening strategic partnerships with global medical imaging equipment manufacturers (OEMs)

Astorg has successfully completed the acquisition of OPEN Health from Amulet Capital Partners, executing a significant secondary buyout in the highly attractive healthcare services sector. Through this transaction, Astorg secures a controlling interest in a premier medical affairs and market access business, while the existing management team will continue to helm the organization. The strategic rationale for Astorg is deeply rooted in acquiring a highly scalable platform investment within the rapidly professionalizing medical communications space

Kersia acquired 100% of Sopura from its shareholders as part of a strategic build-up program. This transaction was integrated into a larger financing package arranged during the acquirer's own ownership transition to a new private equity sponsor. The acquisition represents a major strategic shift, allowing the group to significantly increase its exposure to the beverage industry—moving from less than 2% to over 15% of its pro forma revenue. Strategically, the deal combines the target's specialized brewing hygiene expertise and rinse-free product lines with the acquirer's global food safety platform

IK Investment Partners acquired a majority stake in Kersia from Ardian. This transaction was initiated through exclusive negotiations via the IK IX fund, marking the first deal for this specific vehicle. The investment strategy is focused on supporting the group through its next phase of growth and continuing an active global sector consolidation policy. The project builds on the target's remarkable trajectory, having tripled in size in less than four years through the successive integration of six specialized companies

Clayton, Dubilier & Rice, LLC completed its acquisition of Huntsworth PLC on May 1, 2020. The strategic rationale centers on Huntsworth’s position as a leading pharma commercialization services platform, with a strong Health division contributing roughly 85% of the group’s operating profit. CD&R views the company’s underlying markets as attractive, underpinned by long‑term healthcare trends such as demographic shifts, rising drug innovation, increasing outsourcing of commercial and medical services, and the growing complexity of marketing and access channels for specialized therapies

Spectris plc has successfully finalized the acquisition of 100% of the share capital of the target from a mid-market private equity firm. This strategic transaction represents a definitive step in the group’s evolution toward a combined product-and-service proposition within its specialized materials analysis segment. The strategic rationale for the move centers on the high degree of complementarity between the target’s scientific service capabilities and the acquirer’s established instrumentation expertise, particularly through its existing subsidiary, Malvern Panalytical